Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Victor Gerard DeGruttola, D.Sc.

Title
Institution
Department
Address
Phone

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R37AI051164 (DEGRUTTOLA, VICTOR GERARD) Mar 1, 2002 - Nov 30, 2019
    NIH/NIAID
    Methods to Advance the HIV Prevention Research Agenda
    Role: Principal Investigator
  2. R01AI051164 (DEGRUTTOLA, VICTOR GERARD) Mar 1, 2002 - Nov 30, 2011
    NIH/NIAID
    Methods for Long-Term Follow-Up of HIV-Infected Patients
    Role: Principal Investigator
  3. U01AI038855 (HUGHES, MICHAEL DAVID) Jan 1, 1996 - Dec 31, 2006
    NIH/NIAID
    STATISTICAL AND DATA MANAGEMENT CENTER
    Role: Co-Principal Investigator
  4. R29AI028905 (DEGRUTTOLA, VICTOR GERARD) Dec 1, 1989 - Jul 31, 1996
    NIH/NIAID
    STATISTICAL MODELING OF PROGRESSION OF HIV INFECTION
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Kobe J, Talbot O, Chen I, Eshleman SH, Cummings V, Wheeler D, Mayer KH, DeGruttola V. Short Communication: Viral Genetic Linkage Analysis Among Black Men Who Have Sex With Men (HIV Prevention Trials Network 061). AIDS Res Hum Retroviruses. 2019 May; 35(5):434-436. PMID: 30638029.
    Citations:    Fields:    
  2. Halloran ME, Auranen K, Baird S, Basta NE, Bellan SE, Brookmeyer R, Cooper BS, DeGruttola V, Hughes JP, Lessler J, Lofgren ET, Longini IM, Onnela JP, Özler B, Seage GR, Smith TA, Vespignani A, Vynnycky E, Lipsitch M. Simulations for designing and interpreting intervention trials in infectious diseases. BMC Med. 2017 12 29; 15(1):223. PMID: 29287587.
    Citations:    Fields:    Translation:Humans
  3. Zhao R, Catalano P, DeGruttola VG, Michor F. Estimating mono- and bi-phasic regression parameters using a mixture piecewise linear Bayesian hierarchical model. PLoS One. 2017; 12(7):e0180756. PMID: 28723910.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  4. Balzer L, Staples P, Onnela JP, DeGruttola V. Using a network-based approach and targeted maximum likelihood estimation to evaluate the effect of adding pre-exposure prophylaxis to an ongoing test-and-treat trial. Clin Trials. 2017 Apr; 14(2):201-210. PMID: 28124579.
    Citations:    Fields:    Translation:HumansPHPublic Health
  5. Abuelezam NN, McCormick AW, Fussell T, Afriyie AN, Wood R, DeGruttola V, Freedberg KA, Lipsitch M, Seage GR. Can the Heterosexual HIV Epidemic be Eliminated in South Africa Using Combination Prevention? A Modeling Analysis. Am J Epidemiol. 2016 08 01; 184(3):239-48. PMID: 27416841.
    Citations: 3     Fields:    Translation:HumansPHPublic Health
  6. Prague M, Wang R, Stephens A, Tchetgen Tchetgen E, DeGruttola V. Accounting for interactions and complex inter-subject dependency in estimating treatment effect in cluster-randomized trials with missing outcomes. Biometrics. 2016 12; 72(4):1066-1077. PMID: 27060877.
    Citations: 2     Fields:    Translation:Humans
  7. Gaolathe T, Wirth KE, Holme MP, Makhema J, Moyo S, Chakalisa U, Yankinda EK, Lei Q, Mmalane M, Novitsky V, Okui L, van Widenfelt E, Powis KM, Khan N, Bennett K, Bussmann H, Dryden-Peterson S, Lebelonyane R, El-Halabi S, Mills LA, Marukutira T, Wang R, Tchetgen EJ, DeGruttola V, Essex M, Lockman S. Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey. Lancet HIV. 2016 May; 3(5):e221-30. PMID: 27126489.
    Citations: 28     Fields:    
  8. Wirth KE, Agniel D, Barr CD, Austin MD, DeGruttola V. A composite likelihood approach for estimating HIV prevalence in the presence of spatial variation. Stat Med. 2015 Dec 10; 34(28):3750-9. PMID: 26215657.
    Citations:    Fields:    Translation:HumansPHPublic Health
  9. Novitsky V, Bussmann H, Okui L, Logan A, Moyo S, van Widenfelt E, Mmalane M, Lei Q, Holme MP, Makhema J, Lockman S, Degruttola V, Essex M. Estimated age and gender profile of individuals missed by a home-based HIV testing and counselling campaign in a Botswana community. J Int AIDS Soc. 2015; 18:19918. PMID: 26028155.
    Citations: 2     Fields:    Translation:HumansCells
  10. Shikuma CM, Bennett K, Ananworanich J, Gerschenson M, Teeratakulpisarn N, Jadwattanakul T, DeGruttola V, McArthur JC, Ebenezer G, Chomchey N, Praihirunkit P, Hongchookiat P, Mathajittiphun P, Nakamoto B, Hauer P, Phanuphak P, Phanuphak N. Distal leg epidermal nerve fiber density as a surrogate marker of HIV-associated sensory neuropathy risk: risk factors and change following initial antiretroviral therapy. J Neurovirol. 2015 Oct; 21(5):525-34. PMID: 26002840.
    Citations: 2     Fields:    Translation:HumansCells
  11. Novitsky V, Moyo S, Lei Q, DeGruttola V, Essex M. Importance of Viral Sequence Length and Number of Variable and Informative Sites in Analysis of HIV Clustering. AIDS Res Hum Retroviruses. 2015 May; 31(5):531-42. PMID: 25560745.
    Citations: 2     Fields:    Translation:HumansCells
  12. Lynch ML, DeGruttola V. Predicting time to threshold for initiating antiretroviral treatment to evaluate cost of treatment as HIV prevention. J R Stat Soc Ser C Appl Stat. 2015 Feb 01; 64(2):359-375. PMID: 25620814.
    Citations:    
  13. Novitsky V, Moyo S, Lei Q, DeGruttola V, Essex M. Impact of sampling density on the extent of HIV clustering. AIDS Res Hum Retroviruses. 2014 Dec; 30(12):1226-35. PMID: 25275430.
    Citations: 14     Fields:    Translation:HumansCells
  14. Burns DN, DeGruttola V, Pilcher CD, Kretzschmar M, Gordon CM, Flanagan EH, Duncombe C, Cohen MS. Toward an endgame: finding and engaging people unaware of their HIV-1 infection in treatment and prevention. AIDS Res Hum Retroviruses. 2014 Mar; 30(3):217-24. PMID: 24410300.
    Citations: 12     Fields:    Translation:Humans
  15. Novitsky V, Bussmann H, Logan A, Moyo S, van Widenfelt E, Okui L, Mmalane M, Baca J, Buck L, Phillips E, Tim D, McLane MF, Lei Q, Wang R, Makhema J, Lockman S, DeGruttola V, Essex M. Phylogenetic relatedness of circulating HIV-1C variants in Mochudi, Botswana. PLoS One. 2013; 8(12):e80589. PMID: 24349005.
    Citations: 6     Fields:    Translation:HumansCells
  16. Rubin E, LaVange L, DeGruttola V. University of Pennsylvania 5th annual conference on statistical issues in clinical trials: emerging statistical issues in biomarker validation (afternoon session). Clin Trials. 2013 Oct; 10(5):701-8. PMID: 23988466.
    Citations:    Fields:    Translation:Humans
  17. Valcour VG, Ananworanich J, Agsalda M, Sailasuta N, Chalermchai T, Schuetz A, Shikuma C, Liang CY, Jirajariyavej S, Sithinamsuwan P, Tipsuk S, Clifford DB, Paul R, Fletcher JL, Marovich MA, Slike BM, DeGruttola V, Shiramizu B. HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients. PLoS One. 2013; 8(7):e70164. PMID: 23936155.
    Citations: 35     Fields:    Translation:HumansCells
  18. Izu A, Cohen T, Degruttola V. Bayesian estimation of mixture models with prespecified elements to compare drug resistance in treatment-naïve and experienced tuberculosis cases. PLoS Comput Biol. 2013; 9(3):e1002973. PMID: 23555210.
    Citations: 2     Fields:    Translation:HumansCells
  19. Chalermchai T, Valcour V, Sithinamsuwan P, Pinyakorn S, Clifford D, Paul RH, Tipsuk S, Fletcher JL, Degruttola V, Ratto-Kim S, Hutchings N, Shikuma C, Ananworanich J. Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND. J Neurovirol. 2013 Apr; 19(2):137-43. PMID: 23483520.
    Citations: 6     Fields:    Translation:Humans
  20. Sailasuta N, Ross W, Ananworanich J, Chalermchai T, DeGruttola V, Lerdlum S, Pothisri M, Busovaca E, Ratto-Kim S, Jagodzinski L, Spudich S, Michael N, Kim JH, Valcour V. Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PLoS One. 2012; 7(11):e49272. PMID: 23229129.
    Citations: 45     Fields:    Translation:HumansCellsCTClinical Trials
  21. Shikuma CM, Nakamoto B, Shiramizu B, Liang CY, DeGruttola V, Bennett K, Paul R, Kallianpur K, Chow D, Gavegnano C, Hurwitz SJ, Schinazi RF, Valcour VG. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther. 2012; 17(7):1233-42. PMID: 23018140.
    Citations: 24     Fields:    Translation:HumansCells
  22. Stock S, DeGruttola V. Recursive partitioning for monotone missing at random longitudinal markers. Stat Med. 2013 Mar 15; 32(6):978-94. PMID: 22941582.
    Citations:    Fields:    Translation:HumansCells
  23. Yang Y, DeGruttola V. Resampling-based methods in single and multiple testing for equality of covariance/correlation matrices. Int J Biostat. 2012 Jun 22; 8(1):Article 13. PMID: 22740584.
    Citations:    Fields:    Translation:HumansCells
  24. Wester CW, Eden SK, Shepherd BE, Bussmann H, Novitsky V, Samuels DC, Hendrickson SL, Winkler CA, O'Brien SJ, Essex M, D'Aquila RT, DeGruttola V, Marlink RG. Risk factors for symptomatic hyperlactatemia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical trial. AIDS Res Hum Retroviruses. 2012 Aug; 28(8):759-65. PMID: 22540188.
    Citations: 9     Fields:    Translation:Humans
  25. Shikuma C, Gerschenson M, Ananworanich J, Valcour V, Teeratakulpisarn N, Jadwattanakul T, Degruttola V, Liang CY, McArthur J, Ebenezer G, Chomchey N, Praihirunkit P, Hongchookiath P, Mathajittiphun P, Nakamoto B, Hauer P, Phanuphak P, Phanuphak N. Determinants of epidermal nerve fibre density in antiretroviral-naïve HIV-infected individuals. HIV Med. 2012 Nov; 13(10):602-8. PMID: 22574621.
    Citations: 5     Fields:    Translation:HumansCells
  26. Goyal R, Wang R, DeGruttola V. Editorial commentary: network epidemic models: assumptions and interpretations. Clin Infect Dis. 2012 Jul; 55(2):276-8. PMID: 22491502.
    Citations: 2     Fields:    Translation:HumansCells
  27. Wester CW, Stitelman OM, deGruttola V, Bussmann H, Marlink RG, van der Laan MJ. Effect modification by sex and baseline CD4+ cell count among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trial. AIDS Res Hum Retroviruses. 2012 Sep; 28(9):981-8. PMID: 22309114.
    Citations: 1     Fields:    Translation:Humans
  28. Lok JJ, DeGruttola V. Impact of time to start treatment following infection with application to initiating HAART in HIV-positive patients. Biometrics. 2012 Sep; 68(3):745-54. PMID: 22352840.
    Citations: 2     Fields:    Translation:Humans
  29. Hogan CM, Degruttola V, Sun X, Fiscus SA, Del Rio C, Hare CB, Markowitz M, Connick E, Macatangay B, Tashima KT, Kallungal B, Camp R, Morton T, Daar ES, Little S. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis. 2012 Jan 01; 205(1):87-96. PMID: 22180621.
    Citations: 32     Fields:    Translation:HumansCells
  30. Shikuma CM, Seto T, Liang CY, Bennett K, DeGruttola V, Gerschenson M, Stein JH, Budoff M, Hodis HN, Delaney JA, Ogata-Arakaki D, Pramyothin P, Chow D. Vitamin D levels and markers of arterial dysfunction in HIV. AIDS Res Hum Retroviruses. 2012 Aug; 28(8):793-7. PMID: 21978287.
    Citations: 17     Fields:    Translation:Humans
  31. Merchant RC, Clark MA, Langan TJ, Mayer KH, Seage GR, DeGruttola VG. Can computer-based feedback improve emergency department patient uptake of rapid HIV screening? Ann Emerg Med. 2011 Jul; 58(1 Suppl 1):S114-9.e1-2. PMID: 21684389.
    Citations: 7     Fields:    Translation:HumansPHPublic Health
  32. Hu C, Degruttola V. Recursive partitioning of resistant mutations for longitudinal markers based on a U-type score. Biostatistics. 2011 Oct; 12(4):750-62. PMID: 21596729.
    Citations: 1     Fields:    Translation:HumansCells
  33. DeGruttola V, Schooley RT. Antiretroviral therapy as prevention: linking the mainframe to Main Street. Clin Infect Dis. 2011 Apr 15; 52(8):1050-2. PMID: 21460323.
    Citations: 3     Fields:    Translation:Humans
  34. Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, Hammer SM, Kim JH, Degruttola VG. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis. 2011 Apr 01; 203(7):969-75. PMID: 21402548.
    Citations: 34     Fields:    Translation:Humans
  35. Gezmu M, DeGruttola V, Dixon D, Essex M, Halloran E, Hogan J, Grobler A, Kim S, McDermott J, McKaig R, Neaton JD. Strengthening biostatistics resources in sub-Saharan Africa: research collaborations through U.S. partnerships. Stat Med. 2011 Mar 30; 30(7):695-708. PMID: 21394746.
    Citations: 7     Fields:    Translation:PHPublic Health
  36. Veronese F, Anton P, Fletcher CV, DeGruttola V, McGowan I, Becker S, Zwerski S, Burns D. Implications of HIV PrEP trials results. AIDS Res Hum Retroviruses. 2011 Jan; 27(1):81-90. PMID: 20969483.
    Citations: 6     Fields:    Translation:HumansCells
  37. Kolber MA, Buendia P, Degruttola V, Moore RD. HIV-1 diversity after a class switch failure. AIDS Res Hum Retroviruses. 2010 Nov; 26(11):1175-80. PMID: 20854203.
    Citations:    Fields:    Translation:HumansCells
  38. DeGruttola V, Smith DM, Little SJ, Miller V. Developing and evaluating comprehensive HIV infection control strategies: issues and challenges. Clin Infect Dis. 2010 May 15; 50 Suppl 3:S102-7. PMID: 20397937.
    Citations: 14     Fields:    Translation:HumansPHPublic Health
  39. Novitsky V, Wang R, Bussmann H, Lockman S, Baum M, Shapiro R, Thior I, Wester C, Wester CW, Ogwu A, Asmelash A, Musonda R, Campa A, Moyo S, van Widenfelt E, Mine M, Moffat C, Mmalane M, Makhema J, Marlink R, Gilbert P, Seage GR, DeGruttola V, Essex M. HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission. PLoS One. 2010 Apr 12; 5(4):e10148. PMID: 20405044.
    Citations: 28     Fields:    Translation:AnimalsCellsPHPublic Health
  40. Assoumou L, Cozzi-Lepri A, Brun-Vézinet F, Degruttola V, Kuritzkes DR, Phillips A, Zolopa A, Miller V, Flandre P, Costagliola D. Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. AIDS. 2010 Jan 28; 24(3):365-71. PMID: 19864933.
    Citations: 2     Fields:    Translation:HumansCells
  41. Tournoud M, Etard JF, Ecochard R, DeGruttola V. Adherence to antiretroviral therapy, virological response, and time to resistance in the Dakar cohort. Stat Med. 2010 Jan 15; 29(1):14-32. PMID: 19941299.
    Citations: 1     Fields:    Translation:HumansCells
  42. Wester CW, Thomas AM, Bussmann H, Moyo S, Makhema JM, Gaolathe T, Novitsky V, Essex M, deGruttola V, Marlink RG. Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana. AIDS. 2010 Jan; 24 Suppl 1:S27-36. PMID: 20023437.
    Citations: 19     Fields:    Translation:HumansCells
  43. Merchant RC, Freelove SM, Langan TJ, Clark MA, Mayer KH, Seage GR, DeGruttola VG. The relationship of reported HIV risk and history of HIV testing among emergency department patients. Postgrad Med. 2010 Jan; 122(1):61-74. PMID: 20107290.
    Citations: 4     Fields:    Translation:HumansPHPublic Health
  44. Merchant RC, Clark MA, Langan TJ, Seage GR, Mayer KH, DeGruttola VG. Effectiveness of increasing emergency department patients' self-perceived risk for being human immunodeficiency virus (HIV) infected through audio computer self-interview-based feedback about reported HIV risk behaviors. Acad Emerg Med. 2009 Nov; 16(11):1143-55. PMID: 20053235.
    Citations: 10     Fields:    Translation:HumansPHPublic Health
  45. Buendia P, Cadwallader B, DeGruttola V. A phylogenetic and Markov model approach for the reconstruction of mutational pathways of drug resistance. Bioinformatics. 2009 Oct 01; 25(19):2522-9. PMID: 19654117.
    Citations: 6     Fields:    Translation:Cells
  46. Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, Essex M, Degruttola V, Marlink RG. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. J Acquir Immune Defic Syndr. 2009 May 01; 51(1):37-46. PMID: 19282782.
    Citations: 24     Fields:    Translation:HumansCells
  47. Merchant RC, Clark MA, Seage GR, Mayer KH, Degruttola VG, Becker BM. Emergency department patient perceptions and preferences on opt-in rapid HIV screening program components. AIDS Care. 2009 Apr; 21(4):490-500. PMID: 19283644.
    Citations: 15     Fields:    Translation:HumansPHPublic Health
  48. Valcour VG, Shiramizu BT, Sithinamsuwan P, Nidhinandana S, Ratto-Kim S, Ananworanich J, Siangphoe U, Kim JH, de Souza M, Degruttola V, Paul RH, Shikuma CM. HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study. Neurology. 2009 Mar 17; 72(11):992-8. PMID: 19289739.
    Citations: 38     Fields:    Translation:HumansCells
  49. Merchant RC, Catanzaro BM, Seage GR, Mayer KH, Clark MA, Degruttola VG, Becker BM. Demographic variations in HIV testing history among emergency department patients: implications for HIV screening in US emergency departments. J Med Screen. 2009; 16(2):60-6. PMID: 19564517.
    Citations: 11     Fields:    Translation:HumansPHPublic Health
  50. Merchant RC, Clark MA, Mayer KH, Seage Iii GR, DeGruttola VG, Becker BM. Video as an effective method to deliver pretest information for rapid human immunodeficiency testing. Acad Emerg Med. 2009 Feb; 16(2):124-35. PMID: 19120050.
    Citations: 11     Fields:    Translation:HumansPHPublic Health
  51. DeGruttola V, Little S, Schooley R. Controlling the HIV epidemic, without a vaccine! AIDS. 2008 Nov 30; 22(18):2554-5. PMID: 19005285.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  52. Bussmann H, Wester CW, Ndwapi N, Grundmann N, Gaolathe T, Puvimanasinghe J, Avalos A, Mine M, Seipone K, Essex M, Degruttola V, Marlink RG. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS. 2008 Nov 12; 22(17):2303-11. PMID: 18981769.
    Citations: 68     Fields:    Translation:HumansCells
  53. Merchant RC, Seage GR, Mayer KH, Clark MA, DeGruttola VG, Becker BM. Emergency department patient acceptance of opt-in, universal, rapid HIV screening. Public Health Rep. 2008 Nov-Dec; 123 Suppl 3:27-40. PMID: 19172704.
    Citations: 30     Fields:    Translation:HumansPHPublic Health
  54. Schumi J, Degruttola V. Resampling-based analyses of the effects of combinations of HIV genetic mutations on drug susceptibility. Stat Med. 2008 Oct 15; 27(23):4740-57. PMID: 18186529.
    Citations: 2     Fields:    Translation:Humans
  55. Schumi J, DiRienzo AG, DeGruttola V. Testing for associations with missing high-dimensional categorical covariates. Int J Biostat. 2008 Sep 29; 4(1):Article 18. PMID: 20231909.
    Citations:    Fields:    Translation:HumansCells
  56. Assoumou L, Brun-Vézinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, Zolopa A, Degruttola V, Miller V, Costagliola D. Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. J Infect Dis. 2008 Aug 15; 198(4):470-80. PMID: 18598191.
    Citations: 5     Fields:    Translation:HumansCells
  57. Tai BC, De Stavola BL, de Gruttola V, Gebski V, Machin D. First-event or marginal estimation of cause-specific hazards for analysing correlated multivariate failure-time data? Stat Med. 2008 Mar 15; 27(6):922-36. PMID: 17551931.
    Citations: 3     Fields:    Translation:Humans
  58. Healy BC, DeGruttola VG, Hu C. Accommodating uncertainty in a tree set for function estimation. Stat Appl Genet Mol Biol. 2008; 7(1):Article5. PMID: 18312210.
    Citations: 1     Fields:    Translation:HumansCells
  59. Spritzler J, DeGruttola VG, Pei L. Two-sample tests of area-under-the-curve in the presence of missing data. Int J Biostat. 2008 Jan 17; 4(1):Article 1. PMID: 20231907.
    Citations: 3     Fields:    Translation:Humans
  60. Demeter LM, DeGruttola V, Lustgarten S, Bettendorf D, Fischl M, Eshleman S, Spreen W, Nguyen BY, Koval CE, Eron JJ, Hammer S, Squires K. Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials. 2008 Jan-Feb; 9(1):11-25. PMID: 18215978.
    Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
  61. Wester CW, Okezie OA, Thomas AM, Bussmann H, Moyo S, Muzenda T, Makhema J, van Widenfelt E, Musonda R, Novitsky V, Gaolathe T, Ndwapi N, Essex M, Kuritzkes DR, DeGruttola V, Marlink RG. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr. 2007 Nov 01; 46(3):318-22. PMID: 18090299.
    Citations: 33     Fields:    Translation:Humans
  62. Yang Y, Degruttola V. Resampling-based multiple testing methods with covariate adjustment: application to investigation of antiretroviral drug susceptibility. Biometrics. 2008 Jun; 64(2):329-36. PMID: 17900313.
    Citations:    Fields:    Translation:Cells
  63. Merchant RC, Gee EM, Clark MA, Mayer KH, Seage GR, Degruttola VG. Comparison of patient comprehension of rapid HIV pre-test fundamentals by information delivery format in an emergency department setting. BMC Public Health. 2007 Sep 12; 7:238. PMID: 17850670.
    Citations: 16     Fields:    Translation:Humans
  64. Vaida F, Fitzgerald AP, Degruttola V. Efficient Hybrid EM for Linear and Nonlinear Mixed Effects Models with Censored Response. Comput Stat Data Anal. 2007 Aug 15; 51(12):5718-5730. PMID: 19578533.
    Citations: 10     
  65. Novitsky V, Wester CW, DeGruttola V, Bussmann H, Gaseitsiwe S, Thomas A, Moyo S, Musonda R, Van Widenfelt E, Marlink RG, Essex M. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. AIDS Res Hum Retroviruses. 2007 Jul; 23(7):868-78. PMID: 17678469.
    Citations: 32     Fields:    Translation:HumansCells
  66. Healy B, De Gruttola V, Pagano M. Combining cross-sectional and prospective data methods to improve transition parameter estimation for characterizing the accumulation of HIV-1 drug resistance mutations. Biometrics. 2007 Sep; 63(3):742-50. PMID: 17403101.
    Citations:    Fields:    Translation:Cells
  67. Hu C, De Gruttola V. Joint modeling of progression of HIV resistance mutations measured with uncertainty and failure time data. Biometrics. 2007 Mar; 63(1):60-8. PMID: 17447930.
    Citations: 1     Fields:    Translation:Cells
  68. May S, Degruttola V. Nonparametric tests for two-group comparisons of dependent observations obtained at varying time points. Biometrics. 2007 Mar; 63(1):194-200. PMID: 17447945.
    Citations: 2     Fields:    Translation:HumansCells
  69. Foulkes AS, DeGruttola VG. A resampling-based approach to multiple testing with uncertainty in phase. Int J Biostat. 2007; 3(1):Article 2. PMID: 22550644.
    Citations: 1     Fields:    Translation:HumansCells
  70. Suruki RY, Mueller N, Hayashi K, Harn D, DeGruttola V, Raker CA, Tsubouchi H, Stuver SO. Host immune status and incidence of hepatocellular carcinoma among subjects infected with hepatitis C virus: a nested case-control study in Japan. Cancer Epidemiol Biomarkers Prev. 2006 Dec; 15(12):2521-5. PMID: 17164379.
    Citations: 5     Fields:    Translation:HumansCells
  71. De Gruttola V, Flexner C, Schapiro J, Hughes M, Van Der Laan M, Kuritzkes DR. Drug development strategies for salvage therapy: conflicts and solutions. AIDS Res Hum Retroviruses. 2006 Nov; 22(11):1106-9. PMID: 17147496.
    Citations:    Fields:    Translation:Humans
  72. Healy B, Degruttola V. Hidden Markov models for settings with interval-censored transition times and uncertain time origin: application to HIV genetic analyses. Biostatistics. 2007 Apr; 8(2):438-52. PMID: 16940036.
    Citations: 3     Fields:    Translation:HumansCells
  73. Kassutto S, Maghsoudi K, Johnston MN, Robbins GK, Burgett NC, Sax PE, Cohen D, Pae E, Davis B, Zachary K, Basgoz N, D'agata EM, DeGruttola V, Walker BD, Rosenberg ES. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis. 2006 Apr 01; 42(7):1024-31. PMID: 16511771.
    Citations: 20     Fields:    Translation:HumansCells
  74. De Gruttola S, Boomsma K, Poulikakos D. Computational simulation of a non-newtonian model of the blood separation process. Artif Organs. 2005 Dec; 29(12):949-59. PMID: 16305650.
    Citations: 4     Fields:    Translation:HumansCells
  75. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL, Donahue JP, Kim RB. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005 Dec 01; 192(11):1931-42. PMID: 16267764.
    Citations: 85     Fields:    Translation:Humans
  76. Brown ER, Ibrahim JG, DeGruttola V. A flexible B-spline model for multiple longitudinal biomarkers and survival. Biometrics. 2005 Mar; 61(1):64-73. PMID: 15737079.
    Citations: 28     Fields:    Translation:Humans
  77. De Gruttola V, Foulkes AS. Validation and discovery in Markov models of genetics data. Stat Appl Genet Mol Biol. 2004; 3:Article38. PMID: 16646818.
    Citations: 1     Fields:    
  78. Brun-Vézinet F, Costagliola D, Khaled MA, Calvez V, Clavel F, Clotet B, Haubrich R, Kempf D, King M, Kuritzkes D, Lanier R, Miller M, Miller V, Phillips A, Pillay D, Schapiro J, Scott J, Shafer R, Zazzi M, Zolopa A, DeGruttola V. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther. 2004 Aug; 9(4):465-78. PMID: 15456077.
    Citations: 18     Fields:    Translation:HumansCells
  79. Mildvan D, Bosch RJ, Kim RS, Spritzler J, Haas DW, Kuritzkes D, Kagan J, Nokta M, DeGruttola V, Moreno M, Landay A. Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis. 2004 May 15; 189(10):1811-20. PMID: 15122517.
    Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
  80. Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003 Dec 11; 349(24):2304-15. PMID: 14668456.
    Citations: 55     Fields:    Translation:HumansCellsCTClinical Trials
  81. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dubé MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003 Dec 11; 349(24):2293-303. PMID: 14668455.
    Citations: 85     Fields:    Translation:HumansCellsCTClinical Trials
  82. Hammer SM, Bassett R, Squires KE, Fischl MA, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, DeGruttola V. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther. 2003 Dec; 8(6):507-18. PMID: 14760884.
    Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
  83. Jiang H, Deeks SG, Kuritzkes DR, Lallemant M, Katzenstein D, Albrecht M, DeGruttola V. Assessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis. 2003 Oct 01; 188(7):1001-8. PMID: 14513420.
    Citations: 8     Fields:    Translation:HumansCells
  84. DiRienzo AG, DeGruttola V, Larder B, Hertogs K. Non-parametric methods to predict HIV drug susceptibility phenotype from genotype. Stat Med. 2003 Sep 15; 22(17):2785-98. PMID: 12939786.
    Citations: 10     Fields:    Translation:HumansCells
  85. Foulkes AS, DeGruttola V. Characterizing classes of antiretroviral drugs by genotype. Stat Med. 2003 Aug 30; 22(16):2637-55. PMID: 12898549.
    Citations: 2     Fields:    Translation:HumansCells
  86. Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J Infect Dis. 2003 Jul 15; 188(2):179-93. PMID: 12854072.
    Citations: 10     Fields:    Translation:HumansCells
  87. DiRienzo AG, DeGruttola V. Design and analysis of clinical trials with a bivariate failure time endpoint, with application to AIDS Clinical Trials Group Study A5142. Control Clin Trials. 2003 Apr; 24(2):122-34. PMID: 12689734.
    Citations: 2     Fields:    Translation:Humans
  88. Izazola-Licea JA, Gortmaker SL, de Gruttola V, Tolbert K, Mann J. Sexual behavior patterns and HIV risks in bisexual men compared to exclusively heterosexual and homosexual men. Salud Publica Mex. 2003; 45 Supp 5:S662-71. PMID: 14974278.
    Citations: 5     Fields:    Translation:Humans
  89. Bennett KK, DeGruttola VG, Marschner IC, Havlir DV, Richman DD. Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy. J Acquir Immune Defic Syndr. 2002 Sep 01; 31(1):20-6. PMID: 12352146.
    Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
  90. Fitzgerald AP, DeGruttola VG, Vaida F. Modelling HIV viral rebound using non-linear mixed effects models. Stat Med. 2002 Jul 30; 21(14):2093-108. PMID: 12111889.
    Citations: 7     Fields:    Translation:HumansCells
  91. Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA. 2002 Jul 10; 288(2):169-80. PMID: 12095381.
    Citations: 34     Fields:    Translation:HumansCTClinical Trials
  92. Nokta MA, Holland F, De Gruttola V, Emery VC, Jacobson MA, Griffiths P, Pollard RB, Feinberg JE. Cytomegalovirus (CMV) polymerase chain reaction profiles in individuals with advanced human immunodeficiency virus infection: relationship to CMV disease. J Infect Dis. 2002 Jun 15; 185(12):1717-22. PMID: 12085316.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  93. Foulkes AS, De GV. Characterizing the relationship between HIV-1 genotype and phenotype: prediction-based classification. Biometrics. 2002 Mar; 58(1):145-56. PMID: 11890310.
    Citations: 8     Fields:    Translation:HumansCells
  94. De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, Gail MH, Prentice R, Wittes J, Zeger SL. Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. Control Clin Trials. 2001 Oct; 22(5):485-502. PMID: 11578783.
    Citations: 79     Fields:    Translation:HumansCells
  95. Huang W, De Gruttola V, Fischl M, Hammer S, Richman D, Havlir D, Gulick R, Squires K, Mellors J. Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy. J Infect Dis. 2001 May 15; 183(10):1455-65. PMID: 11319681.
    Citations: 8     Fields:    Translation:HumansCells
  96. Smeaton LM, DeGruttola V, Robbins GK, Shafer RW. ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1. Control Clin Trials. 2001 Apr; 22(2):142-59. PMID: 11306153.
    Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
  97. Gilbert PB, DeGruttola V, Hammer SM, Kuritzkes DR. Virologic and regimen termination surrogate end points in AIDS clinical trials. JAMA. 2001 Feb 14; 285(6):777-84. PMID: 11176916.
    Citations: 2     Fields:    Translation:Humans
  98. Schooley RT, Spino C, Kuritzkes D, Walker BD, Valentine FA, Hirsch MS, Cooney E, Friedland G, Kundu S, Merigan TC, McElrath MJ, Collier A, Plaeger S, Mitsuyasu R, Kahn J, Haslett P, Uherova P, deGruttola V, Chiu S, Zhang B, Jones G, Bell D, Ketter N, Twadell T, Chernoff D, Rosandich M. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. J Infect Dis. 2000 Nov; 182(5):1357-64. PMID: 11023459.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  99. Gilbert PB, Hanna GJ, De Gruttola V, Martinez-Picado J, Kuritzkes DR, Johnson VA, Richman DD, D'Aquila RT. Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens. AIDS Res Hum Retroviruses. 2000 Sep 20; 16(14):1325-36. PMID: 11018852.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  100. Sevin AD, DeGruttola V, Nijhuis M, Schapiro JM, Foulkes AS, Para MF, Boucher CA. Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333. J Infect Dis. 2000 Jul; 182(1):59-67. PMID: 10882582.
    Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
  101. Kim S, Hughes MD, Hammer SM, Jackson JB, DeGruttola V, Katzenstein DA. Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. AIDS Res Hum Retroviruses. 2000 May 01; 16(7):645-53. PMID: 10791875.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  102. Litwack RS, Gilligan DM, DeGruttola V. Beta-blockade for patients undergoing vascular surgery. N Engl J Med. 2000 Apr 06; 342(14):1052; author reply 1052-3. PMID: 10755897.
    Citations:    Fields:    Translation:Humans
  103. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L, Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther. 2000 Mar; 5(1):41-8. PMID: 10846592.
    Citations: 55     Fields:    Translation:HumansCells
  104. Izazola-Licea JA, Gortmaker SL, De Gruttola V, Tolbert K, Mann J. Assessment of non-response bias in a probability household survey of male same-gender sexual behavior. Salud Publica Mex. 2000 Mar-Apr; 42(2):90-8. PMID: 10893978.
    Citations:    Fields:    Translation:Humans
  105. Goebel FD, Mannhalter JW, Belshe RB, Eibl MM, Grob PJ, de Gruttola V, Griffiths PD, Erfle V, Kunschak M, Engl W. Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group. AIDS. 1999 Aug 20; 13(12):1461-8. PMID: 10465068.
    Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
  106. Kim S, De Gruttola V. Strategies for cohort sampling under the Cox proportional hazards model, application to an AIDS clinical trial. Lifetime Data Anal. 1999 Jun; 5(2):149-72. PMID: 10408182.
    Citations: 3     Fields:    Translation:Humans
  107. Murphy RL, Gulick RM, DeGruttola V, D'Aquila RT, Eron JJ, Sommadossi JP, Currier JS, Smeaton L, Frank I, Caliendo AM, Gerber JG, Tung R, Kuritzkes DR. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis. 1999 Apr; 179(4):808-16. PMID: 10068575.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  108. Marschner IC, Betensky RA, DeGruttola V, Hammer SM, Kuritzkes DR. Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Mar 01; 20(3):220-7. PMID: 10077169.
    Citations: 7     Fields:    Translation:HumansCells
  109. Wu H, Ding AA, De Gruttola V. Why are the decay rates in plasma HIV-1 different for different treatments and in different patient populations? AIDS. 1999 Feb 25; 13(3):429-30. PMID: 10199240.
    Citations: 2     Fields:    Translation:HumansCells
  110. Wu H, Ding AA, De Gruttola V. Estimation of HIV dynamic parameters. Stat Med. 1998 Nov 15; 17(21):2463-85. PMID: 9819839.
    Citations: 26     Fields:    Translation:Humans
  111. Litwack RS, DeGruttola V. Predicting long-term postoperative cardiovascular outcomes. Anesthesiology. 1998 Nov; 89(5):1286-8. PMID: 9822031.
    Citations:    Fields:    Translation:Humans
  112. Gilbert P, DeGruttola V, Hammer S. Efficient trial designs for studying combination antiretroviral treatments in patients with various resistance profiles. J Infect Dis. 1998 Aug; 178(2):340-8. PMID: 9697713.
    Citations: 1     Fields:    Translation:Humans
  113. Zackin R, Marschner I, Andersen J, Cowles MK, De Gruttola V, Hammer S, Fischl M, Cotton D. Perspective: human immunodeficiency virus type 1 (HIV-1) RNA end points in HIV clinical trials: issues in interim monitoring and early stopping. J Infect Dis. 1998 Mar; 177(3):761-5. PMID: 9498459.
    Citations:    Fields:    Translation:HumansCells
  114. DeGruttola V, Hughes M, Gilbert P, Phillips A. Trial design in the era of highly effective antiviral drug combinations for HIV infection. AIDS. 1998; 12 Suppl A:S149-56. PMID: 9632997.
    Citations: 3     Fields:    Translation:HumansCells
  115. Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, Hammer SM, Hughes MD, Johnson VA, Katzenstein DA, Richman DD, Smeaton LM, Spector SA, Saag MS. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis. 1998 Jan; 177(1):40-7. PMID: 9419168.
    Citations: 21     Fields:    Translation:HumansCellsCTClinical Trials
  116. Lin DY, Fleming TR, De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med. 1997 Jul 15; 16(13):1515-27. PMID: 9249922.
    Citations: 114     Fields:    Translation:Humans
  117. Fleming TR, DeGruttola V, DeMets DL. Surrogate endpoints. AIDS Clin Rev. 1997-1998; 129-43. PMID: 9305447.
    Citations: 1     Fields:    Translation:Humans
  118. LaValley MP, DeGruttola V. Models for empirical Bayes estimators of longitudinal CD4 counts. Stat Med. 1996 Nov 15-30; 15(21-22):2289-305; discussion 2337-40. PMID: 8931202.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  119. Cohen CJ, Hellinger JA, Day J, Salitsky N, Shevitz A, Zackin R, DeGruttola V. Lack of effect of cimetidine on lymphocyte subsets in patients infected with human immunodeficiency virus type 1. Clin Infect Dis. 1996 Nov; 23(5):1049-54. PMID: 8922801.
    Citations:    Fields:    Translation:HumansCellsCTClinical Trials
  120. Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB, DeGruttola V, Crumpacker CS, Kahn J. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Dis. 1996 Oct; 174(4):704-12. PMID: 8843206.
    Citations: 23     Fields:    Translation:HumansCells
  121. Ragni MV, Amato DA, LoFaro ML, DeGruttola V, Van Der Horst C, Eyster ME, Kessler CM, Gjerset GF, Ho M, Parenti DM, et al. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups. Blood. 1995 May 01; 85(9):2337-46. PMID: 7727768.
    Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
  122. D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, Richman DD. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med. 1995 Mar 15; 122(6):401-8. PMID: 7856987.
    Citations: 51     Fields:    Translation:HumansCellsCTClinical Trials
  123. Fiscus SA, DeGruttola V, Gupta P, Katzenstein DA, Meyer WA, LoFaro ML, Katzman M, Ragni MV, Reichelderfer PS, Coombs RW. Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis. 1995 Feb; 171(2):305-11. PMID: 7844365.
    Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
  124. Hughes MD, DeGruttola V, Welles SL. Evaluating surrogate markers. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10 Suppl 2:S1-8. PMID: 7552506.
    Citations: 5     Fields:    Translation:Humans
  125. Gauvreau K, Degruttola V, Pagano M, Bellocco R. The effect of covariates on the induction time of AIDS using improved imputation of exact seroconversion times. Stat Med. 1994 Oct 15-30; 13(19-20):2021-30. PMID: 7846407.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  126. DeGruttola V, Beckett LA, Coombs RW, Arduino JM, Balfour HH, Rasheed S, Hollinger FB, Fischl MA, Volberding P. Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories. J Infect Dis. 1994 Apr; 169(4):713-21. PMID: 8133085.
    Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
  127. DeGruttola V, Seage GR, Mayer KH, Horsburgh CR. Infectiousness of HIV between male homosexual partners. J Clin Epidemiol. 1989; 42(9):849-56. PMID: 2789269.
    Citations: 28     Fields:    Translation:Humans
  128. DeGruttola V, Mayer KH. Human immunodeficiency virus and oral intercourse. Ann Intern Med. 1987 Sep; 107(3):428-9. PMID: 3619236.
    Citations: 6     Fields:    Translation:Humans
  129. Kleinman JC, DeGruttola VG, Cohen BB, Madans JH. Regional and urban-suburban differentials in coronary heart disease mortality and risk factor prevalence. J Chronic Dis. 1981; 34(1):11-9. PMID: 7451636.
    Citations: 6     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu).
DeGruttola's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (340)
Explore
_
Co-Authors (53)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.